drugset / Trial / NCT04722575
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
Phase 2
Active not recruiting
95 enrolled
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Neoadjuvant plus adjuvant treatment with target therapy and immunotherapy given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma (stage III B / C / D and oligometastatic stage IV).
Timeline
- Start
- 2020-12-03
- Primary completion
- 2023-12-15
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | Intravenous |
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Cobimetinib | Small molecule | 60 mg | Oral |
| Subject | Vemurafenib | Small molecule | 720 mg | Oral |
| Subject | Vemurafenib | Small molecule | 960 mg | Oral |